Monoclonal antibody · Agonist of DR5 (TNFRSF10B) · developed by Inhibrx Biosciences
Ozekibart is a recombinant, humanized, tetravalent monoclonal antibody that binds four DR5 receptors per molecule, mimicking the natural TRAIL ligand. It activates DR5 and the death receptor signaling pathway, triggering caspase cascades and tumor cell apoptosis. It is studied in chondrosarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04950075 | Phase 2 | Conventional Chondrosarcoma | Active not recruiting | INBX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Conventional Chondrosarcoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the INBX page.
See INBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INBX catalysts and pipeline →